Table 2.
Cox regression for overall survival
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Male | 1.699 (0.864–3.340) | 0.124 | 1.160 (0.465–2.893) | 0.750 |
| Age group (≤ 65 years) | 0.640 (0.315–1.300) | 0.217 | 1.049 (0.446–2.464) | 0.913 |
| Smoker | 1.325 (0.613–2.868) | 0.474 | 1.139 (0.419–3.095) | 0.798 |
| ECOG PS = 0 | 0.403 (0.196–0.828) | 0.013 | 0.464 (0.208–1.037) | 0.061 |
| CNS metastases | 1.092 (0.551–2.165) | 0.800 | 1.778 (0.789–4.004) | 0.165 |
| Continued osimertinib | 0.914 (0.461–1.811) | 0.796 | 0.510 (0.190–1.372) | 0.182 |
| Chemotherapy post-PD | 0.535 (0.248–1.156) | 0.112 | 0.265 (0.097–0.722) | 0.009 |
| Dramatic PD | 4.579 (2.289–9.161) | 0.000 | 4.126 (1.865–9.129) | 0.000 |
CI confidence interval, CNS central nervous system, ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio, PD progressive disease